Exclusive patent and know-how license to develop, use, sell, offer for sale, have sold, import, export, commercialize and sublicense, with nonexclusive rights to manufacture pharmaceutical products containing the D-63153 compound, which is a LHRH antagonist, as an active ingredient alone or as combination-preparations, for all human uses, including for oncology, such as benign hyperplasia, prostate cancer, and related endometriosis.

This entry describes a licensing agreement for the pharmaceutical compound D-63153, a LHRH antagonist intended for commercialization in human applications. The text identifies oncology indications such as benign hyperplasia and prostate cancer, while explicitly listing endometriosis as one of the therapeutic areas covered by the license. RoyaltyStat is presented as the database platform providing analytics and data on such intellectual property transfers rather than a primary research study. Relevance to endometriosis: listed as one indication for GnRH antagonists, though the paper's main focus is uterine fibroids.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works